By Suherman Candra Maholtra 
A comprehensive new study involving more than 33,000 patients has provided the most robust evidence to date that nicotinamide, a specific form of vitamin B3, can substantially lower the risk of developing common skin cancers. The research, led by investigators at Vanderbilt University Medical Center and the Department of Veterans Affairs (VA), marks a pivotal moment in dermatological prevention strategies. By analyzing a massive dataset of veterans, researchers found that while the supplement offers a modest 14% reduction in overall skin cancer risk, its efficacy skyrockets to a 54% reduction when administered immediately after a patient’s first diagnosis of skin cancer. These findings suggest a major shift in clinical practice, moving away from reactive treatment toward early-stage chemoprevention for millions of at-risk individuals.
The study, published in a leading medical journal, addresses a long-standing gap in dermatological knowledge. For nearly a decade, clinicians have debated the efficacy of nicotinamide based on smaller clinical trials. This new data, pulled from the VA Corporate Data Warehouse, provides the scale necessary to confirm that vitamin B3 is not just a theoretical benefit but a practical, low-cost tool for preventing nonmelanoma skin cancers, particularly cutaneous squamous cell carcinoma. As skin cancer remains the most common form of malignancy in the United States, with millions of new cases diagnosed annually, the implications of a widely available, over-the-counter preventative measure are profound.
Historical Context: From the ONTRAC Trial to Large-Scale Validation
The medical community’s interest in nicotinamide as a chemopreventive agent was ignited in 2015 following the publication of the Oral Nicotinamide to Reduce Actinic Cancer (ONTRAC) trial. That study, conducted in Australia, involved 386 participants and found that taking 500 milligrams of nicotinamide twice daily reduced the incidence of new nonmelanoma skin cancers by 23% compared to a placebo group. While the results were promising, the small sample size and the specific geographic focus led some experts to call for more extensive validation.
Following the 2015 trial, many dermatologists began recommending nicotinamide to "high-risk" patients—typically defined as those who had already suffered from multiple skin cancers. However, because nicotinamide is an over-the-counter supplement rather than a prescription drug, tracking its long-term efficacy in the general population proved difficult. Most medical records do not consistently log supplement use, making large-scale retrospective studies nearly impossible in conventional hospital settings.
The breakthrough for the Vanderbilt research team came through the VA’s unique healthcare infrastructure. Unlike most private health systems, the VA includes nicotinamide on its official formulary. This meant that every time a veteran was "prescribed" the supplement by a VA physician, the dosage, duration, and subsequent health outcomes were recorded in a centralized database. This allowed Dr. Lee Wheless and his colleagues to bypass the limitations of previous studies and analyze a cohort of 33,833 veterans—nearly 100 times the size of the original 2015 study.
Detailed Methodology and Patient Demographics
The research team focused on a specific treatment regimen: 500 milligrams of nicotinamide taken twice daily for a minimum of 30 days. To ensure the integrity of the data, the researchers established a baseline for each patient, tracking their dermatological history before and after the initiation of the supplement. Of the total 33,833 veterans reviewed, 12,287 were identified as nicotinamide users, while a control group of 21,479 patients did not receive the supplement.
The study population was primarily composed of older veterans, a demographic that is disproportionately affected by skin cancer due to cumulative sun exposure and age-related declines in DNA repair mechanisms. The researchers specifically tracked the subsequent diagnoses of the two most common forms of nonmelanoma skin cancer: basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (SCC).
By utilizing the VA’s Corporate Data Warehouse, the team was able to account for various confounding factors, including the number of previous skin cancers, the timing of the supplement initiation, and the presence of underlying health conditions. This granular level of detail allowed the researchers to identify not just if nicotinamide worked, but when it worked most effectively.
Key Findings: The Critical Importance of Timing
The most striking revelation of the study was the correlation between the timing of nicotinamide use and the degree of risk reduction. The data revealed a hierarchy of effectiveness:
- Overall Risk Reduction: Across the entire study population, nicotinamide users saw a 14% decrease in the risk of developing a new skin cancer.
- Early Intervention: For patients who began taking the supplement immediately after their very first skin cancer diagnosis, the risk reduction was a staggering 54%.
- Late-Stage Intervention: Paradoxically, the benefit of the supplement appeared to diminish for patients who had already developed multiple skin cancers (three or more) before starting the regimen.
- Cancer Type Specificity: The protective effect was most pronounced for squamous cell carcinoma (SCC), which is generally considered more aggressive and more likely to metastasize than basal cell carcinoma.
Dr. Lee Wheless, the study’s corresponding author and an assistant professor of Dermatology and Medicine at Vanderbilt University Medical Center, noted that these results challenge the current clinical status quo. "These results would really shift our practice from starting it once patients have developed numerous skin cancers to starting it earlier," Wheless stated. The data suggests that the window of maximum opportunity for chemoprevention is much earlier in the disease progression than previously believed.
Biological Mechanism: How Vitamin B3 Protects the Skin
To understand why nicotinamide is effective, it is necessary to look at the cellular impact of ultraviolet (UV) radiation. When skin is exposed to UV light, it causes DNA damage and depletes cellular energy in the form of adenosine triphosphate (ATP). This "energy crisis" within the skin cells hampers the natural DNA repair processes and leads to the suppression of the local immune system, creating an environment where cancerous cells can thrive.
Nicotinamide is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme essential for ATP production. By boosting NAD+ levels, nicotinamide helps:
- Restore Cellular Energy: It provides the "fuel" necessary for skin cells to initiate DNA repair after UV damage.
- Reduce Immunosuppression: It prevents the UV-induced dampening of the immune response in the skin, allowing the body to identify and destroy precancerous cells more effectively.
- Inhibit Inflammation: Chronic inflammation is a known driver of carcinogenesis; nicotinamide has demonstrated anti-inflammatory properties that may further mitigate risk.
The study’s findings regarding squamous cell carcinoma are particularly relevant here. SCC is highly associated with cumulative UV damage and immunosuppression. The fact that nicotinamide showed the strongest effect against SCC reinforces the theory that the supplement works primarily by bolstering the skin’s internal defense and repair mechanisms.
Findings in Immunocompromised and Transplant Patients
A significant portion of the study was dedicated to a high-risk sub-group: 1,334 patients who were immunocompromised due to solid organ transplants. These patients are traditionally at a much higher risk for skin cancer—sometimes up to 100 times the risk of the general population—because the medications required to prevent organ rejection also suppress the body’s ability to surveil and eliminate cancerous skin cells.
In this group, the researchers found that the overall risk reduction was not statistically significant. This suggests that for those with severely suppressed immune systems, the modest boost provided by nicotinamide may not be enough to overcome the profound vulnerability caused by transplant-related medications. However, there was a silver lining: even in this group, early use of nicotinamide was linked to a lower incidence of cutaneous squamous cell carcinoma, suggesting that while it may not be a silver bullet for transplant patients, it still holds some value in a multi-modal prevention strategy.
Clinical Implications and the Future of Preventative Care
The Vanderbilt-VA study has immediate implications for dermatologists and primary care physicians. For years, the lack of large-scale data led to a "wait and see" approach, where nicotinamide was reserved for patients whose skin cancer had already become a chronic problem. This study argues for a more proactive stance.
If the 54% risk reduction for early-intervention patients holds true in broader clinical practice, it could lead to a significant decrease in the number of surgical procedures performed each year. Most nonmelanoma skin cancers are treated via Mohs surgery or standard excision—procedures that, while effective, are costly and can result in significant scarring. A daily supplement that costs only pennies could potentially save the healthcare system billions of dollars in surgical costs.
However, Dr. Wheless cautioned that more work is needed to refine these prevention strategies. "We still need to do a better job of identifying who will actually benefit, as roughly only half of patients will develop multiple skin cancers," he explained. The challenge for future research will be to identify the specific biomarkers or clinical profiles that predict which patients are most likely to progress from a single skin cancer to a recurring condition.
Conclusion and Research Support
The study represents a successful collaboration between academic medicine and the veteran healthcare system. Supported by a Department of Veterans Affairs grant (IK2CX002452), the research team included a diverse group of experts from Vanderbilt, including Katyln Knox, Rachel Weiss, Siwei Zhang, PhD, Lydia Yao, MS, Yaomin Xu, PhD, and Kyle Maas.
As the medical community digests these findings, the focus will likely shift toward updating clinical guidelines. If nicotinamide becomes a standard recommendation following a patient’s first nonmelanoma skin cancer diagnosis, it could mark one of the most significant advancements in skin cancer prevention since the widespread adoption of sunscreen. For the millions of people at risk, this large-scale validation of a simple vitamin offers a clear path toward reducing the burden of the world’s most common cancer.
